David MacFarlane - Titan Pharmaceuticals Independent Director
TTNP Stock | USD 7.16 0.22 2.98% |
Director
Dr. M. David MacFarlane, Ph.D., is Independent Director of Titan Pharmaceuticals, Inc. David MacFarlane, Ph.D. served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989 until his retirement in August 1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice President of Regulatory Affairs. Based on Dr. MacFarlanes management experience in the pharmaceutical industry, particularly in the area of clinical and regulatory affairs, our Board believes that Dr. MacFarlane has the appropriate set of skills to serve as a member of the Board. since 2002.
Age | 73 |
Tenure | 22 years |
Professional Marks | CFA |
Address | 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
Phone | 650 244 4990 |
Web | https://www.titanpharm.com |
Titan Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6111) % which means that it has lost $0.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0554) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/29/2024, Return On Capital Employed is likely to grow to -7.83. In addition to that, Return On Assets is likely to grow to -2.74. At this time, Titan Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/29/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Liabilities And Stockholders Equity is likely to drop slightly above 3.5 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Lian Goldstein | Shagrir Group Vehicle | 42 | |
Larry Switzer | American Axle Manufacturing | 68 | |
Bill Gossman | NLIGHT Inc | 56 | |
Herbert Parker | American Axle Manufacturing | 63 | |
James McCaslin | American Axle Manufacturing | 72 | |
Elizabeth Chappell | American Axle Manufacturing | 63 | |
Gail Hamilton | Arrow Electronics | 71 | |
Philip Asherman | Arrow Electronics | 67 | |
Laurel Krzeminski | Arrow Electronics | 66 | |
David Anderson | Modine Manufacturing | 71 | |
Shai Cohen | Shagrir Group Vehicle | 50 | |
Dana Yosef | Shagrir Group Vehicle | 39 | |
Steven Hantler | American Axle Manufacturing | 62 | |
John Smith | American Axle Manufacturing | 70 | |
Stephen Patrick | Arrow Electronics | 71 | |
Sandra Pierce | American Axle Manufacturing | 62 | |
Jason Parsons | American Axle Manufacturing | N/A | |
David Bills | Modine Manufacturing | 59 | |
Gary Locke | NLIGHT Inc | 68 | |
Suresh Garimella | Modine Manufacturing | 56 | |
Kevin Penn | American Axle Manufacturing | N/A |
Management Performance
Return On Equity | -1.06 | ||||
Return On Asset | -0.61 |
Titan Pharmaceuticals Leadership Team
Elected by the shareholders, the Titan Pharmaceuticals' board of directors comprises two types of representatives: Titan Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Titan. The board's role is to monitor Titan Pharmaceuticals' management team and ensure that shareholders' interests are well served. Titan Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Titan Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Rubin, Executive Chairman of the Board | ||
Rajinder Kumar, Director | ||
Brian Crowley, Senior Administration | ||
Sunil Bhonsle, President, Secretary and Director | ||
James McNab, Director | ||
Federico Recli, Director | ||
David MacFarlane, Independent Director | ||
Joseph Akers, Director | ||
Eurelio Cavalier, Independent Director | ||
Marc MD, Ex Director | ||
David Lazar, Principal Officer | ||
Scott Smith, Director | ||
Joe Schrei, Executive Operations | ||
Katherine BeebeDeVarney, COO President | ||
Ley Smith, Independent Director | ||
Dane Hallberg, Executive Vice President and Chief Commercial Officer | ||
Jennifer Kiernan, Executive Coordinator | ||
Victor Bauer, Independent Director | ||
Seghi Recli, Lead Director | ||
Mike Fritz, National Director |
Titan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Titan Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.06 | ||||
Return On Asset | -0.61 | ||||
Operating Margin | (515.25) % | ||||
Current Valuation | (1.68 M) | ||||
Shares Outstanding | 807.45 K | ||||
Shares Owned By Insiders | 47.82 % | ||||
Shares Owned By Institutions | 6.02 % | ||||
Number Of Shares Shorted | 12.04 K | ||||
Price To Earning | (3.60) X | ||||
Price To Book | 0.72 X |
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.20) | Revenue Per Share 0.409 | Quarterly Revenue Growth (0.96) | Return On Assets (0.61) | Return On Equity (1.06) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.